NEWTON, Mass., June 1, 2026
Karyopharm Therapeutics has announced that it will host an investor conference call featuring leading hematology expert Dr. John Mascarenhas, principal investigator of the pivotal Phase 3 SENTRY trial, following the presentation of key clinical findings at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The event underscores growing interest in the development of selinexor in combination with ruxolitinib as a potential new treatment approach for patients with myelofibrosis, a rare and debilitating blood cancer characterized by bone marrow scarring, chronic inflammation, and impaired blood cell production. As one of the most closely watched late-stage clinical programs in hematologic oncology, the SENTRY trial represents a significant milestone in Karyopharm’s strategy to expand the clinical utility of its first-in-class XPO1 inhibitor platform. The conference call will provide expert insights into the trial’s findings, clinical significance, and future implications for patients living with myelofibrosis, a disease that continues to present substantial unmet medical needs despite advances in targeted therapies.
Phase 3 SENTRY Trial Strengthens Focus on Myelofibrosis Innovation
The Phase 3 SENTRY study is evaluating selinexor combined with ruxolitinib in patients with myelofibrosis, a chronic myeloproliferative neoplasm associated with significant morbidity and reduced quality of life. While current therapies such as JAK inhibitors have improved symptom management and disease control, many patients continue to experience disease progression, treatment resistance, or inadequate responses. Researchers believe that targeting nuclear export pathways through XPO1 inhibition may offer a differentiated therapeutic strategy capable of enhancing treatment outcomes.
Selinexor, Karyopharm’s lead oncology asset, has already established a clinical presence in multiple myeloma and continues to be investigated across a broad range of hematologic and solid tumor indications. The SENTRY trial was designed to determine whether combining selinexor with standard-of-care ruxolitinib could improve efficacy while maintaining an acceptable safety profile. Data presented at ASCO are expected to provide important evidence regarding the potential role of this combination regimen in addressing unmet needs within the myelofibrosis treatment landscape.
Expert Perspectives Highlight Clinical Importance of SENTRY Data
Advertisement
A key feature of Karyopharm’s post-ASCO event is the participation of Dr. John Mascarenhas, a globally recognized authority in myeloproliferative neoplasms and Director of the Center of Excellence for Blood Cancers and Myeloid Disorders at Mount Sinai. As principal investigator of the SENTRY trial, Dr. Mascarenhas will discuss the clinical relevance of the findings and their potential impact on future treatment paradigms. The involvement of leading clinical investigators reflects the growing scientific interest surrounding novel approaches to treating blood cancers driven by complex molecular pathways.
Hematology specialists continue to seek therapies capable of delivering durable disease control while improving symptoms, reducing spleen enlargement, and enhancing overall patient outcomes. Clinical data generated from late-stage studies such as SENTRY play a critical role in shaping regulatory strategies, treatment guidelines, and future standards of care. As precision medicine continues to evolve within hematologic malignancies, therapies targeting previously underexplored biological mechanisms may offer meaningful new opportunities for patients who require additional treatment options.
Expanding the Potential of Nuclear Export Inhibition in Oncology
Karyopharm’s broader oncology strategy centers on advancing therapies based on nuclear export inhibition, a mechanism designed to restore tumor suppressor function and inhibit cancer cell survival. The company’s flagship therapy, XPOVIO® (selinexor), has already secured approvals in multiple countries for relapsed or refractory multiple myeloma and continues to serve as the foundation for additional clinical development programs. Beyond myelofibrosis, Karyopharm is exploring selinexor and next-generation compounds across various hematologic and solid tumors, including endometrial cancer and other genetically defined malignancies.
The SENTRY trial represents one of the company’s most significant late-stage development efforts and could potentially broaden the clinical applications of nuclear export inhibition in oncology. As cancer research increasingly focuses on targeted and mechanism-driven therapies, the successful advancement of selinexor in myelofibrosis could further strengthen Karyopharm’s position within the competitive oncology landscape. The ASCO presentation and subsequent expert discussion are expected to provide valuable insights into how innovative therapeutic combinations may help address persistent challenges in blood cancer treatment while supporting future clinical development initiatives.
Source: Karyopharm Therapeutics press release
